MFG
PTCT icon

Merit Financial Group’s PTC Therapeutics PTCT Stock Holding History

Merit Financial Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,028
Closed -$205K – 1739
2025
Q1 		$205K Buy
+4,028
New +$201K ﹤0.01% 1292

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Merit Financial Group's PTCT Position: Q2 2025 in Review

Merit Financial Group sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 4,028 shares — an estimated $205K sold.

Merit Financial Group first reported a position in PTCT in Q1 2025 and held it in 1 quarter. The position peaked at $205K in Q1 2025. 284 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • Merit Financial Group reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Merit Financial Group sold 4,028 PTC Therapeutics shares in Q2 2025, an estimated $205K.
  • Merit Financial Group first reported a position in PTC Therapeutics in Q1 2025 and held it in 1 quarter.
  • Merit Financial Group's PTC Therapeutics position peaked at $205K in Q1 2025.
  • 284 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Merit Financial Group's 13F filing for Q2 2025, filed 22 Jul 2025.